The sentence of the "cancellation of benefit reduction" lawsuit of the brain function improvement drug Choline Alfoscerate has been postponed again.

According to the industry on the 16th, the 6th part of the Seoul Administrative Court changed the date of the lawsuit for cancellation of the notification of the application of health insurance drugs screening benefits scheduled for the 17th to July 22. It is a trial of a lawsuit filed by Chong Kun Dang Group to cancel the reduction of α-GPC benefit. In August 2020, the MOHW issued a partial revision notice of "details on the criteria and methods of care benefits" containing the contents of α-GPC's new benefit standards. If a patient who has not been diag